About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Study Finds New Drug to Effectively Fight Latent TB

by Rajashri on September 15, 2008 at 3:06 PM
Font : A-A+

 Study Finds New Drug to Effectively Fight Latent TB

An investigative drug, called R207910, can effectively fight against latent bacteria that causes tuberculosis (TB), a new study by an Indian origin scientist has found.

R207910 is currently in clinical trials against multi-drug resistant tuberculosis strains, and scientists are hoping that it may now lead to improved and shortened treatments for this globally prevalent disease.

Advertisement

It is estimated that one third of the world population is infected, asymptomatically, with latent TB and is at risk of developing active TB disease during their life time.

In the new study, Anil Koul and colleagues at Johnson and Johnson, tested R207910 on dormant M. tuberculosis in three different laboratory models of latency. R207910 targets a protein (ATP synthase) essential for making cellular energy (ATP) in actively replicating TB.
Advertisement

According to the scientists, even dormant bacteria, which are usually physiologically "turned off", still need to produce small quantities of ATP to survive. Already, a block in ATP synthesis can be considered an Achilles heel for killing dormant bacteria.

This reasoning proved to be correct and R207190 could successfully destroy dormant bacteria by greater than 95 percent, while current drugs like isoniazid showed no effect.

To their surprise, they found that R207910 is slightly more effective in killing dormant bacteria as compared to actively replicating ones, a unique spin as all known TB drugs are more effective on replicating bugs.

Now, researchers hope to validate these results clinically, and note that ATP synthase should be looked at as a drug target for other persistent bacterial infections.

Source: ANI
RAS/L
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Memory Loss - Can it be Recovered?
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity AIDS/HIV Clinical Trials - Different Phases of the trial Signature Drug Toxicity 

Recommended Reading
Tuberculosis
Tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lung. It may spread to ......
How Tuberculosis Dupes the Immune System: Study
Scientists have figured out how tuberculosis tricks the immune system, a discovery that could lead ....
A Promising Live Vaccine Against Tuberculosis Enters Trial in Germany
In the first phase of clinical trials in Neuss, Germany a promising live vaccine against ......
AIDS/HIV
"AIDS is an epidemic disease, a potentially preventable, deadly infection for which there is no cure...
Clinical Trials - Different Phases of the trial
Clinical trials serve as a vital component for improving the treatment of medical conditions as they...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use